Investment Overview
Cencora, Inc. (COR), the Pennsylvania-headquartered pharmaceutical sourcing and distribution services company, reported its fiscal year 2026 second-quarter results yesterday, prompting a fall in its share price from >$305 per share to ~$250.
The company earned revenues of $78.4bn, up 3.8% year-on-year, and reported gross profit of $3.6bn, up 17%, and operating income of $1.1bn, up 10% year-on-year. Diluted earnings per share increased by 129% year-on-year to $8.4. Guidance for the full year 2026 was provided as per the slide below (taken from Cencora’s earnings presentation):
Analysis: Why Did The Market Punish An Apparently Strong Set Of Results?
Cencora – formerly known as Amerisource Bergen – is valued at a market cap of $49bn today, meaning its forward price-to-sales (“P/S”) ratio, based on 2026 full-year revenue guidance of ~$337.4bn at the midpoint, is ~0.15x.
That is a shockingly low figure – I doubt many businesses generating revenues in the triple-digit billions can match it – which usually indicates a business is in some kind of trouble – over-burdened with debt and on the brink of collapse, for example, or losing tens of billions of dollars per annum.
Cencora, however, trades at a forward price-to-earnings ratio of ~14, which is another positive metric – this is a reasonably profitable business – while its level of debt does not seem onerous, either. Long-term debt stands at just over $12bn; according to Seeking Alpha, the current portion of long-term debt stands at ~$203m, and cash and equivalents stand at ~$2.2bn.
The issue that Wall Street seems to have had with Cencora’s earnings is that revenues fell short of expectations (although Cencora still bet on EPS), and as we can see in the table above, they were down sequentially by >$7bn, although seemingly, this is not untypical for this particular quarter.
The last
